Differentiating Factors of Abemaciclib Among the CDK 4/6 Inhibitors for Breast Cancer

Video

Hope S. Rugo, MD, discusses the differentiating factors of abemaciclib among the CDK 4/6 inhibitors for breast cancer treatment.

Related Videos
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
Related Content